Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Guangzhou Magpie Pharma Completes $15 Million B Round

publication date: Feb 13, 2019

Guangzhou Magpie Pharmaceutical completed a $15 million B funding from Sangel Capital. Magpie is an innovative company that is developing drugs based on modernized formulations of proven TCM drugs. It aims to discover drugs that are either best-in-class or first-in-class. Its most advanced candidate is a nitrone triazine (TBN) treatment for ischemic stroke, currently in a China Phase I trial. The company said it hopes to have between four and six candidates in clinical trials within three years. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital